Table 1 Correlation between PAFAH1B3 expression and different clinicopathological Characteristics of clinical LUAD patients
From: PAFAH1B3 predicts poor prognosis and promotes progression in lung adenocarcinoma
Characteristics | n | PAFAH1B3 | Pearson χ2 | P value | |
|---|---|---|---|---|---|
Low or no expression | High expression | ||||
Total | 79 | 25(31.6) | 54(68.4) | ||
Age(y) | |||||
<60 | 39 | 13(33.3) | 26(66.7) | 0.101 | 0.75 |
≥ 60 | 40 | 12(30.0) | 28(70.0) | ||
Gender | |||||
Male | 41 | 13(31.7) | 28(68.3) | 0.000 | 0.990 |
Female | 38 | 12(31.6) | 26(68.4) | ||
Primary tumor | |||||
T1 | 20 | 5(25.0) | 15(75.0) | 0.835 | 0.659 |
T2 | 38 | 14(36.8) | 24(63.2) | ||
T3 + T4 | 18 | 6(33.3) | 12(66.7) | ||
Unknown | 3 | 0(0.0) | 3(100.0) | ||
Lymph node metastasis | |||||
No | 38 | 15(39.5) | 23(60.5) | 1.874 | 0.171 |
Yes | 40 | 10(25.0) | 30(75.0) | ||
Unknown | 1 | 0(0.0) | 1(100.0) | ||
Distant metastasis | |||||
No | 64 | 24(37.5) | 40(62.5) | 5.341 | 0.021* |
Yes | 15 | 1(6.7) | 14(93.3) | ||
TNM stage | |||||
stage I | 19 | 11(57.9) | 8(42.1) | 11.47 | 0.009** |
stage II | 19 | 4(21.1) | 15(78.9) | ||
stage III | 26 | 9(34.6) | 17(65.4) | ||
stage IV | 15 | 1(6.7) | 14(93.3) | ||
Vital status | |||||
Alive | 30 | 14(46.7) | 16(53.3) | 5.045 | 0.025* |
Dead | 49 | 11(22.4) | 38(77.6) | ||